Visualization of KCa3.1 Channels in Tumor Cells by Optimized Senicapoc-Bodipy Conjugates

IF 3.7 Q1 CHEMISTRY, MEDICINAL
Insa Thale, Joana Massa, Elke Naß, Laura Vinnenberg, Luca Matteo Todesca, Thomas Budde, Iván Maisuls, Cristian A. Strassert, Oliver Koch, Albrecht Schwab and Bernhard Wünsch*, 
{"title":"Visualization of KCa3.1 Channels in Tumor Cells by Optimized Senicapoc-Bodipy Conjugates","authors":"Insa Thale,&nbsp;Joana Massa,&nbsp;Elke Naß,&nbsp;Laura Vinnenberg,&nbsp;Luca Matteo Todesca,&nbsp;Thomas Budde,&nbsp;Iván Maisuls,&nbsp;Cristian A. Strassert,&nbsp;Oliver Koch,&nbsp;Albrecht Schwab and Bernhard Wünsch*,&nbsp;","doi":"10.1021/acsptsci.5c00510","DOIUrl":null,"url":null,"abstract":"<p >Upregulation of K<sub>Ca</sub>3.1 channels was observed in highly aggressive tumor cells, such as non small cell lung cancer cells of the A549 line. In order to visualize K<sub>Ca</sub>3.1 channels in these cells, novel fluorescent probes with increased polarity were designed. Key step of the synthesis was a 1,3-dipolar cycloaddition of senicapoc propargyl ether <b>4</b> with various azide substituted bodipy dyes. Due to their reduced lipophilicity and promising photophysical properties, the senicapoc-bodipy conjugates <b>7a</b> (log<i>P</i> = 4.3) and <b>16</b> (log<i>P</i> = 4.4) were able to stain K<sub>Ca</sub>3.1 ion channels in fixed, living, and permeabilized A549–3R tumor cells. The apparent size of the observed fluorescent dots indicates labeling of single K<sub>Ca</sub>3.1 channels. The recorded density is in good accordance with literature values. The specificity of K<sub>Ca</sub>3.1 labeling by the senicapoc-bodipy conjugates <b>7a</b> and <b>16</b> was shown with HEK293 cells, blocking experiments and azide precursors. Subsequent staining of K<sub>Ca</sub>3.1 ion channels with hydroxyphenyl derivative <b>16</b> and antibodies did not lead to overlapping (yellow) dots, as different states of the ion channel were stained by <b>16</b> (open state) and antibody (closed state). In patch clamp experiments, both senicapoc-bodipy conjugates <b>7a</b> and <b>16</b> reduced the current density, although less efficiently than senicapoc. MD simulations showed weaker interactions of the amide moiety of <b>16</b> with Thr250, explaining the lower channel inhibition of the open-pore blocker <b>16</b> compared to senicapoc (<b>1</b>). Due to their optimal imaging properties, high specificity, balanced lipophilicity/hydrophilicity, and sufficient water solubility, senicapoc-bodipy conjugates <b>7a</b> and <b>16</b> represent innovative diagnostic tools to image K<sub>Ca</sub>3.1 channels.</p>","PeriodicalId":36426,"journal":{"name":"ACS Pharmacology and Translational Science","volume":"8 9","pages":"3371–3388"},"PeriodicalIF":3.7000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Pharmacology and Translational Science","FirstCategoryId":"1085","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsptsci.5c00510","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Upregulation of KCa3.1 channels was observed in highly aggressive tumor cells, such as non small cell lung cancer cells of the A549 line. In order to visualize KCa3.1 channels in these cells, novel fluorescent probes with increased polarity were designed. Key step of the synthesis was a 1,3-dipolar cycloaddition of senicapoc propargyl ether 4 with various azide substituted bodipy dyes. Due to their reduced lipophilicity and promising photophysical properties, the senicapoc-bodipy conjugates 7a (logP = 4.3) and 16 (logP = 4.4) were able to stain KCa3.1 ion channels in fixed, living, and permeabilized A549–3R tumor cells. The apparent size of the observed fluorescent dots indicates labeling of single KCa3.1 channels. The recorded density is in good accordance with literature values. The specificity of KCa3.1 labeling by the senicapoc-bodipy conjugates 7a and 16 was shown with HEK293 cells, blocking experiments and azide precursors. Subsequent staining of KCa3.1 ion channels with hydroxyphenyl derivative 16 and antibodies did not lead to overlapping (yellow) dots, as different states of the ion channel were stained by 16 (open state) and antibody (closed state). In patch clamp experiments, both senicapoc-bodipy conjugates 7a and 16 reduced the current density, although less efficiently than senicapoc. MD simulations showed weaker interactions of the amide moiety of 16 with Thr250, explaining the lower channel inhibition of the open-pore blocker 16 compared to senicapoc (1). Due to their optimal imaging properties, high specificity, balanced lipophilicity/hydrophilicity, and sufficient water solubility, senicapoc-bodipy conjugates 7a and 16 represent innovative diagnostic tools to image KCa3.1 channels.

Abstract Image

利用优化的Senicapoc-Bodipy偶联物可视化肿瘤细胞中KCa3.1通道
在高侵袭性肿瘤细胞中,如A549系的非小细胞肺癌细胞中,观察到KCa3.1通道上调。为了可视化这些细胞中的KCa3.1通道,设计了一种极性增加的新型荧光探针。合成的关键步骤是用各种叠氮化物取代体染料对四溴丙基醚4进行1,3-偶极环加成。由于其降低的亲脂性和良好的光物理性质,senicapoc-bodipy偶联物7a (logP = 4.3)和16 (logP = 4.4)能够在固定的、活的和通透的A549-3R肿瘤细胞中染色KCa3.1离子通道。观察到的荧光点的表观大小表明标记了单个KCa3.1通道。记录的密度与文献值吻合较好。在HEK293细胞、阻断实验和叠氮化物前体中显示了senicapoc-bodipy偶联物7a和16标记KCa3.1的特异性。随后用羟基苯基衍生物16和抗体对KCa3.1离子通道进行染色,由于不同状态的离子通道分别用16(开放状态)和抗体(封闭状态)染色,因此没有出现重叠(黄色)点。在膜片钳实验中,senicapoc-bodipy共轭物7a和16都降低了电流密度,尽管效率不如senicapoc。MD模拟显示16的酰胺部分与Thr250的相互作用较弱,这解释了与senicapoc相比,开放孔阻滞剂16的通道抑制较低(1)。由于其最佳的成像特性、高特异性、平衡的亲脂/亲水性和足够的水溶性,senicapoc-bodipy偶联物7a和16代表了成像KCa3.1通道的创新诊断工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Pharmacology and Translational Science
ACS Pharmacology and Translational Science Medicine-Pharmacology (medical)
CiteScore
10.00
自引率
3.30%
发文量
133
期刊介绍: ACS Pharmacology & Translational Science publishes high quality, innovative, and impactful research across the broad spectrum of biological sciences, covering basic and molecular sciences through to translational preclinical studies. Clinical studies that address novel mechanisms of action, and methodological papers that provide innovation, and advance translation, will also be considered. We give priority to studies that fully integrate basic pharmacological and/or biochemical findings into physiological processes that have translational potential in a broad range of biomedical disciplines. Therefore, studies that employ a complementary blend of in vitro and in vivo systems are of particular interest to the journal. Nonetheless, all innovative and impactful research that has an articulated translational relevance will be considered. ACS Pharmacology & Translational Science does not publish research on biological extracts that have unknown concentration or unknown chemical composition. Authors are encouraged to use the pre-submission inquiry mechanism to ensure relevance and appropriateness of research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信